Nilo Therapeutics: Pioneering a Novel Neuro-Immunology Approach to Autoimmune Disease with $101M Series A
The treatment of autoimmune diseases is often a balancing act: suppressing the immune system to quell the attack on the body, while concurrently leaving patients vulnerable to infection and other complications. Now, a new biotech startup, nilo Therapeutics, is challenging this paradigm. Launching with a substantial $101 million Series A financing round, Nilo is developing a fundamentally different approach – one that doesn’t suppress the immune system, but rebalances it by targeting the neural circuits that govern immune function.
This isn’t simply a tweak on existing therapies; it represents a potential paradigm shift in how we understand and treat autoimmune disorders. Let’s delve into the science, the strategy, and the implications of Nilo’s innovative approach.
The Brain-Immune Connection: A Newly Explored Frontier
For decades, the immune system and the nervous system were largely considered separate entities. However, mounting research reveals a deeply interconnected relationship. This bidirectional communication, often referred to as neuro-immunology, is now recognized as crucial for maintaining immune homeostasis – the delicate balance that prevents the immune system from overreacting or underreacting.
nilo Therapeutics is specifically focusing on neural circuits – interconnected networks of neurons within the central nervous system responsible for processing specific information.These circuits aren’t just involved in thought and movement; they play a critical role in regulating systemic inflammation.
“We’re looking at the brain not as a passive observer, but as an active controller of the immune system,” explains Laurens Kruidenier, Nilo’s Chief Scientific Officer. “By modulating these ‘master regulator’ circuits, we believe we can achieve a more precise and durable control of immune responses.”
The Zuker Lab breakthrough: Identifying the ”On/Off” Switch for Inflammation
Nilo’s scientific foundation stems from the groundbreaking research of Dr. Charles Zuker at Columbia University. Dr. Zuker’s lab identified specific neurons within the vagus nerve – a cranial nerve connecting the brain to many organs – that directly regulate systemic immune activation and inflammation.
Published last year in Nature, Dr. Zuker’s research demonstrated that stimulating these specific neurons could effectively dampen inflammatory responses in preclinical models. This discovery pinpointed a potential “on/off” switch for inflammation, offering a targeted approach to immune modulation. (You can find the published research here).
Why This Approach Matters: Beyond Immune Suppression
Conventional immunosuppressant drugs often cast a wide net, suppressing various aspects of the immune system. While effective in managing symptoms, this broad suppression comes with notable drawbacks:
* Increased Risk of Infection: A weakened immune system is less able to fight off pathogens.
* Therapeutic Resistance: The immune system can adapt and become resistant to the effects of the drug.
* Limited Long-Term Efficacy: Chronic suppression can lead to further immune dysregulation.
Nilo’s approach aims to circumvent these limitations.By targeting specific neural circuits, they hope to:
* Modulate multiple Immune Pathways: Influence a broader range of immune responses with a single intervention.
* Reduce the Risk of Resistance: Targeting the brain’s control mechanisms may be less prone to adaptive resistance.
* Restore Immune Balance: Rather than simply suppressing the immune system, aim to restore its natural regulatory function.
Nilo’s Path Forward: from Bench to Bedside
The $101 million Series A financing will fuel Nilo’s growth in several key areas:
* Establishing R&D Laboratories: Building state-of-the-art facilities in New York to support their research efforts.
* Expanding the R&D team: Recruiting top talent in neuro-immunology, drug discovery, and clinical development.
* Advancing Preclinical Programs: Further investigating the therapeutic potential of their approach in various disease models.
While Nilo hasn’t yet disclosed the specific autoimmune diseases they are initially targeting, they emphasize the broad applicability of their platform to a wide spectrum of conditions with significant unmet needs. This includes diseases like rheumatoid arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis – conditions affecting millions worldwide.
Leadership and Investment: A Strong Foundation for Success
Nilo’s founding team comprises leading experts in neuro-immunology: Charles Zuker (Columbia University),
Related reading